Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
ID: 357006Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357006

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-036.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting research grant applications for the development and application of novel positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging ligands aimed at enhancing drug discovery and understanding central nervous system (CNS) disorders. This funding opportunity seeks to stimulate research that evaluates new radioligands capable of assessing molecular targets related to CNS disorders, thereby contributing to the understanding of disease mechanisms and the evaluation of therapeutic candidates. The initiative is particularly significant for advancing neuroimaging techniques, especially in the context of mental health and aging-related conditions. Applications are due starting January 5, 2025, with a maximum project period of five years, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-036.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-036-Full-Announcement.html
    PAR-25-036.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), invites research grant applications focused on developing PET and SPECT imaging ligands to study brain disorders. This funding opportunity aims to stimulate research into novel radioligands that can assess molecular targets related to central nervous system (CNS) disorders, thus aiding in understanding disease mechanisms and evaluating therapeutic candidates. Applications are due starting January 5, 2025, with a maximum project period of five years. Eligible applicants include higher education institutions, non-profits, for-profits, and government entities. The grants may cover projects involving clinical trials, but prior approvals are necessary. Comprehensive guidelines include expectations for rigorous research design, feasibility assessments, and justification for the proposed work. Collaborations with academic and industry partners are encouraged to accelerate the identification and development of relevant imaging probes. The application review process will prioritize the significance, innovation, approach, and expertise of the applicants, emphasizing the development of non-redundant tracers and adherence to NIH policies on data sharing and human subjects protections. This initiative is a critical step in advancing neuroimaging techniques for better understanding and treatment of CNS disorders, especially focusing on mental health and aging-related conditions.
    Similar Opportunities
    Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at the development and application of positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging ligands as biomarkers for drug discovery and studies of central nervous system (CNS) disorders. This initiative invites research grant applications that propose the development and evaluation of novel radioligands for human brain imaging, with an emphasis on their potential to enhance understanding and treatment of mental disorders such as depression and cognitive decline. The program supports both clinical and preclinical projects, encouraging collaborative research between academia and industry, and requires applications to justify the relevance and feasibility of their proposed tracers. Interested applicants should note that the submission deadline is May 7, 2026, and can find more details and guidelines at the NIH Grants Information website or by contacting grantsinfo@nih.gov.
    Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at the development and application of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, specifically as biomarkers for drug discovery and studies related to central nervous system (CNS) disorders. This initiative invites applications focused on preclinical development, emphasizing the need for collaborative research between academia and industry to enhance understanding of brain disorders and support drug development processes. The funding opportunity is open to a diverse range of eligible institutions, including those serving underrepresented groups, with a submission deadline of May 7, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents." This initiative aims to advance research in determining optimal dosing strategies for new psychiatric medications in children and adolescents suffering from serious mental illnesses, focusing on the development of central nervous system (CNS) tools and models to assess medication effects on the brain. The opportunity is particularly relevant for researchers with expertise in pediatric psychiatry, neuroimaging, and clinical pharmacology, as it seeks to improve the safety and effectiveness of pediatric clinical trials through the establishment of pharmacodynamic measures. Interested applicants can reach out to Dr. Margaret C. Grabb at mgrabb@mail.nih.gov or by phone at 301-443-3563 for further information, with the estimated synopsis post date set for December 13, 2025, and the close date anticipated for February 13, 2026.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Imaging - Science Track Award for Research Transition (I/START)" aimed at advancing neuroimaging methodologies relevant to substance use disorder (SUD) research. This program encourages both new and established investigators to conduct small "proof-of-concept" studies within a one-year project period, with a funding ceiling of $150,000. The initiative is designed to lower barriers for researchers in adopting advanced imaging techniques, thereby contributing to significant advancements in understanding and addressing substance use challenges. Interested applicants can find more information and application details at the provided link, with the application deadline set for January 7, 2028.
    Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders through a phased grant mechanism (R61/R33). This funding opportunity aims to enhance the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and improve clinical care decisions. The initiative emphasizes the importance of multidisciplinary collaboration and requires applicants to validate biomarkers in a phased approach, with the R61 phase focusing on proof of concept studies and the R33 phase on preliminary clinical validation. Interested applicants should note that the application deadline is January 7, 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.